Scorpius Holdings Announces Removal of NYSE American Trading Suspension; Expected to Resume Normal Trading on August 2, 2024
30 Juillet 2024 - 2:00PM
Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or “the
Company”), an integrated contract development and manufacturing
organization (“CDMO”), today announced that the staff of NYSE
Regulation has withdrawn its delisting determination and will be
lifting the trading suspension of the Company's common stock on the
NYSE American. The NYSE Regulation staff determined that the
Company's common stock was now trading above the threshold of low
selling price issues as further defined by Section 1003(f)(v) of
the NYSE American Company Guide. Scorpius’ common stock is expected
to resume trading on the NYSE American on Friday, August 2, 2024,
under the symbol "SCPX" and Cusip “42237K 508.”
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated
contract development and manufacturing organization (CDMO) focused
on rapidly advancing biologic and cell therapy programs to the
clinic and beyond. Scorpius offers a broad array of analytical
testing, process development, and manufacturing services to
pharmaceutical and biotech companies at its state-of-the-art
facilities in San Antonio, Texas. With an experienced team and new,
purpose-built U.S. facilities, Scorpius is dedicated to transparent
collaboration and flexible, high-quality biologics
biomanufacturing. For more information, please visit
www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. In some cases, forward-looking statements can be
identified by terminology such as "may," "should," "potential,"
"continue," "expects," "anticipates," "intends," "plans,"
"believes," "estimates," and similar expressions, and include
statements regarding the Common Stock resuming trading on the NYSE
American on Friday, August 2, 2024, under the symbol "SCPX."
Important factors that could cause actual results to differ
materially from current expectations include, among others, the
ability of the Company to resume trading on Friday, August 2, 2024
and have its Common Stock remain listed and recommence trading on
the NYSE American; the Company’s financing needs; its cash balance
being sufficient to sustain operations and its ability to raise
capital when needed; the Company’s ability to leverage fixed costs
and achieve long-term profitability; the Company’s ability to
obtain regulatory approvals or to comply with ongoing regulatory
requirements; regulatory limitations relating to the Company’s
ability to successfully promote its services and compete as a pure-
play CDMO; and other factors described in the Company’s annual
report on Form 10-K for the year ended December 31, 2023,
subsequent quarterly reports on Form 10-Qs and any other filings
the Company makes with the SEC. The information in this
presentation is provided only as of the date presented, and the
Company undertakes no obligation to update any forward-looking
statements contained in this presentation on account of new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations ContactDavid
Waldman+1 919 289 4017ir@scorpiusbiologics.com
Scorpius (AMEX:SCPX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Scorpius (AMEX:SCPX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024